10 May 2025 in European Journal of Cardio-Thoracic Surgery
OBJECTIVES: Randomized clinical trials (RCTs) are the gold standard for comparative effectiveness. However, they face unique challenges in cardiac surgery. The objective of this work is to summarize the challenges of RCTs in cardiac surgery, describe efforts employed in recent years to mitigate these impediments and outline the future opportunities for increased RCT adoption in the specialty. METHODS: This review was conducted as an expert analysis on the existing state of RCTs in cardiac surgery based on expert discussion at a dedicated session during the 2024 Annual Meeting of the European Association for Cardio-Thoracic Surgery (EACTS). Different trial-support infrastructures, such as the Randomized Comparison of the Clinical Outcomes of Single versus Multiple Arterial Grafts (ROMA) Network, the Cardiothoracic Surgical Trials Network (CTSN), the Global Cardiovascular Research Funders Forum (GCRFF) and the UK Model, and their respective mechanisms for overcoming RCT barriers were described in detailed. Models were selected due to specific author involvement and knowledge. Future directions were postulated based on current trends. RESULTS: Despite heterogeneous structures, the described models largely aimed to increased cardiac RCTs through improved trial participation, either via increased trainees, expanded stakeholders or focused patient recruitment, facilitating funding and fostering wider collaboration. CONCLUSIONS: RCTs are a key component for clinical advancement yet have been underutilized in cardiac surgery. Recent endeavours have reduced the multifactorial barriers associated with cardiac surgery RCTs and intentional future efforts are necessary for continued cardiac advancement.
22 May 2025 in European Heart Journal
13 November 2025 in European Journal of Cardio-Thoracic Surgery
Objectives: Women patients with aortic stenosis (AS) exhibit distinct anatomic and physiologic features that may influence outcomes after valve replacement. While transcatheter aortic valve replacement (TAVR) has shown early advantages over surgical aortic valve replacement (SAVR) in women, long-term sex-specific outcomes remain unclear. To evaluate outcomes at 5 years comparing TAVR versus SAVR a systematic review and meta-analysis was performed. Methods: A systematic literature review was conducted, identifying all randomized controlled trials (RCTs) comparing TAVR with SAVR which included women with completed 5-year follow-up. The primary outcome was the composite of all-cause mortality or disabling stroke. Meta-analysis was performed using both random-effects and fixed-effect models. The study protocol was registered in PROSPERO (CRD420251004394). Results: Six RCTs were included with a total of 3094 women (1587 TAVR and 1507 SAVR). Overall, no significant difference was observed in the primary outcome between TAVR and SAVR (incidence rate ratios [IRRs] 1.00, 95% confidence interval [CI]: 0.88-1.13, P = .98). Meta-regression did not find any association between key clinical covariates and the primary outcome. Trial sequential analysis demonstrated that the extracted sample size met the required information size, but a definitive treatment effect was not confirmed. Conclusions: While TAVR shows an advantage over SAVR at 1-year follow-up in women, all-cause mortality or disabling stroke is similar in TAVR and SAVR at 5 years. Future studies must include sex-disaggregated reporting of both primary and secondary outcomes in order to comprehensively weigh risks and benefits of each intervention and inform personalized treatment strategies. Clinical registration number: The study protocol was registered in PROSPERO (CRD420251004394).
21 April 2026 in Journal of the American Heart Association
Background: Patient–surgeon sex concordance influences postoperative outcomes in general surgery, but its relevance in cardiac surgery is unknown. Methods: This was a cohort study of 223 065 Medicare beneficiaries undergoing coronary artery bypass grafting, surgical aortic valve replacement, and/or proximal aortic surgery from 2010 to 2021, stratified by surgeon and patient sex. The primary and secondary outcomes were composites of mortality and morbidity (myocardial infarction, stroke, and all‐cause readmission) at 30 days and 5 years postoperatively, respectively. Multivariable regression analysis identified independent associations. Results: The male surgeon–male patient group comprised 59.9% (133 533/223 065), the female surgeon–male patient group comprised 8.3% (18 623/223 065), the female surgeon–female patient group comprised 3.8% (8466/223 065), and the male surgeon–female patient group comprised 28.0% (62 443/223 065) of the cohort. There was no difference in the incidence of the 30‐day composite outcome between groups and no independent association of sex concordance with the 30‐day composite outcome (odds ratio sex discordance, 1.00 [95% CI, 0.96–1.04]; P =0.84); the interaction between patient sex and sex discordance was not significant ( P =0.75). The incidence of the 5‐year composite outcome was higher in the male surgeon–male patient than the female surgeon–male patient group (67.2% [89 795/133 533] versus 65.3% [12 160/18 623]; P <0.0001), and in the male surgeon–female patient than the female surgeon–female patient group (75.7% [47 262/62 443] versus 74.0% [6264/8466]; P =0.0006). There was no association of sex concordance with the 5‐year composite outcome (hazard ratio sex discordance, 1.00 [95% CI, 0.98–1.02]; P =0.69); the interaction between patient sex and sex discordance was not significant ( P =0.89). Conclusions: There was no independent association of patient–surgeon sex concordance with 30‐day or 5‐year outcomes after cardiac surgery.
19 August 2025 in Journal of Surgical Research
21 July 2026 in The Journal of Thoracic and Cardiovascular Surgery